RCAMU
PBYI icon

Rothschild & Co Asset Management US’s Puma Biotechnology PBYI Stock Holding History

Rothschild & Co Asset Management US’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,828
Closed -$730K – 373
2019
Q1 		$730K Sell
18,828
-16,552
-47% -$506K 0.01% 338
2018
Q4 		$720K Buy
35,380
+113
+0.3% +$3.39K 0.01% 361
2018
Q3 		$1.62M Buy
35,267
+3,895
+12% +$188K 0.02% 345
2018
Q2 		$1.86M Buy
31,372
+3,795
+14% +$220K 0.02% 340
2018
Q1 		$1.88M Sell
27,577
-3,189
-10% -$239K 0.02% 318
2017
Q4 		$3.04M Sell
30,766
-2,176
-7% -$243K 0.03% 302
2017
Q3 		$3.94M Sell
32,942
-462
-1% -$43K 0.04% 285
2017
Q2 		$2.92M Buy
33,404
+9,658
+41% +$540K 0.03% 306
2017
Q1 		$883K Sell
23,746
-430
-2% -$15.7K 0.01% 375
2016
Q4 		$742K Buy
24,176
+19,836
+457% +$858K 0.01% 424
2016
Q3 		$291K Buy
+4,340
New +$219K 0.01% 515

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Rothschild & Co Asset Management US's PBYI Position: Q2 2019 in Review

Rothschild & Co Asset Management US sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 18,828 shares — an estimated $730K sold.

Rothschild & Co Asset Management US first reported a position in PBYI in Q3 2016 and held it in 11 quarters. The position peaked at $3.94M in Q3 2017. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

  • Rothschild & Co Asset Management US reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 18,828 Puma Biotechnology shares in Q2 2019, an estimated $730K.
  • Rothschild & Co Asset Management US first reported a position in Puma Biotechnology in Q3 2016 and held it in 11 quarters.
  • Rothschild & Co Asset Management US's Puma Biotechnology position peaked at $3.94M in Q3 2017.
  • 139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2019, filed 25 Jul 2019.